Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs

Incyte (INCY) PT Lowered to $87 at RBC Capital, 'Buyers on Weakness'

February 8, 2022 3:54 PM EST

RBC Capital analyst Brian Abrahams lowered the price target on Incyte (NASDAQ: INCY) to $87.00 (from $90.00) while maintaining an Outperform rating and said they would buy on weakness.

The analyst commented, "4Q featured strong initial launch metrics for Opzelura, solid sales for INCY's core MF... More

Incyte (INCY) Misses Q4 EPS by 76c

February 8, 2022 7:05 AM EST

Incyte (NASDAQ: INCY) reported Q4 EPS of $0.10, $0.76 worse than the analyst estimate of $0.86. Revenue for the quarter came in at $862.85 million versus the consensus estimate of $815.3 million.

For earnings history and earnings-related data on Incyte (INCY) click here.

... More